Home » Newsletters » BioWorld Science

BioWorld Science

Jan. 11, 2016

View Archived Issues

BioMed X and J&J to develop biofilm inhibitors for oral health applications

ChemoCentryx provides update on CCX-168

Verastem initiates phase I trial of defactinib, pembrolizumab and gemcitabine in pancreatic cancer

SolaranRx enters into CRADA with NCI to advance metastatic melanoma theranostic

Peregrine and NCCN establish research collaboration to advance development of bavituximab

C4 Therapeutics launches from Dana-Farber, enters collaboration with Roche

Principia advances two programs in clinic

ViiV Healthcare and Janssen to collaborate to develop rilpivirine and cabotegravir regimen

Gilead reports topline data from phase III studies of tenofovir alafenamide in chronic HBV

uniQure reports on low-dose cohort in phase I/II hemophilia B trial of AMT-060

X-Chem forms discovery collaboration with Sanofi

Checkpoint Therapeutics to obtain rights to Teva's oral PARP inhibitor

Aridis reports promising phase I data on Aerucin

Gruenenthal discloses CRAC blockers

NKTT-120 reduces iNKT cells in patients with sickle cell disease

Bayer Schering Pharma reports BRD4 inhibitors

The University of Montana presents SLC7A11 inhibitors

Johnson & Johnson Innovation discloses a plethora of new collaborations

XBiotech reports data from phase III European trial of Xilonix

AbbVie begins phase III program evaluating ABT-494 for rheumatoid arthritis

Gruenenthal and Akashi Therapeutics form joint drug development program for HT-100

PSMA-targeted ACCURIN shows promise for mCRPC

ImaginAb presents data on PSMA imaging agent for diagnosis of prostate cancer

PTC Therapeutics completes rolling NDA for Translarna, submits phase III data to EMA

FDA grants orphan drug designation to components of Immune Design's CMB-305

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for June 4, 2026.
ASCO 2026: A revolution in pancreatic cancer
BioWorld
At the 2026 American Society of Clinical Oncology (ASCO) Annual Meeting, Revolution Medicines Inc. followed up its stellar top-line data with the details from the...
News in brief
BioWorld Asia
BioWorld Asia briefs for June 2, 2026
EASL 2026: Emerging liver disease targets to watch
BioWorld
At the recently concluded European Association for the Study of the Liver meeting, presentations underscored how increasingly granular insights into liver...
ASCO 2026: PD-(L)1 x VEGF bispecifics fight it out
BioWorld
Multiple companies are chasing Akeso Inc. and Summit Therapeutics Inc. in the battle to potentially dethrone Keytruda (pembrolizumab, Merck & Co. Inc.) as the top...